News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Capital return
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Belite Bio (BLTE) is currently undervalued by 21% according to Simply Wall St. following the FDA's acceptance of its New Drug Application for tinlarebant with Priority Review. Despite a recent one-day dip, the stock has shown strong momentum over the last month and year, …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Belite Bio (BLTE) is back in focus after the FDA accepted its New Drug Application for tinlarebant with Priority Review, a key regulatory step that …
Belite Bio CEO Lin Yu-Hsin sold 365 American depositary shares worth over $65,000 on August 12, 2026, as part of a Rule 10b5-1 trading plan. Despite the stock's remarkable 141% return over the past year, shares have recently declined to $166.28 from the transaction …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Belite Bio stock has delivered a very large 431.2% return over the past three years, while its valuation checks and current market multiples point to …
Benchmark reiterated a Buy rating and a $217.00 price target for Belite Bio (NASDAQ:BLTE) after the FDA granted Priority Review to the company's New Drug Application for Tinlarebant, setting a PDUFA target date of February 12, 2027. The company plans a commercial launch in …
Fidelity National Financial, Inc. (FNF) has reported a beneficial ownership of 5,937,500 shares of Aevex Corp.'s Class A Common Stock, representing a 5.2% voting stake. This investment is held through its wholly-owned subsidiary, National Alliance Group, LLC, with FNF maintaining sole voting and dispositive …
Belite Bio CEO Yu-Hsin Lin sold 365 shares of the company's stock for a total of $65,827.75, reducing his ownership by 0.21%. Despite the sale, analyst sentiment remains largely positive with a "Moderate Buy" consensus and a target price of $204.40, especially following the …
Mizuho has increased its price target for Belite Bio (NASDAQ:BLTE) to $220 from $215, while reaffirming an Outperform rating on the stock. This adjustment reflects a continued positive outlook from the analyst firm. The biopharmaceutical company is focused on developing novel therapeutics for retinal …
This article first appeared on GuruFocus. Release Date: August 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Belite Bio Inc (NASDAQ:BLTE) received FDA acceptance of its New Drug Application (NDA) for Tinlarabant …
Earnings Call Insights: Belite Bio (BLTE) Q2 2026 MANAGEMENT VIEW * Dr. Tom Lin (Chairman of the Board of Directors & CEO) framed the quarter around U.S. regulatory timing, saying, "the FDA has accepted our new drug application for Tinlarebant with priority review and …
Fidelity National Information Services Inc (FIS) stock rose 5.3% to $44.13 on August 13, 2026, and is considered significantly undervalued with a GF Value™ of $91.37, indicating a 51.7% margin of safety. Despite a GF Score™ of 62/100 suggesting above-average investment quality, it carries …
Belite Bio reported a smaller-than-expected loss in Q2 2026, beating EPS estimates, but its stock still slipped. The company's lead candidate, tinlarebant for Stargardt disease, received priority review from the FDA, with a PDUFA date of February 12, 2027. Despite rising R&D and SG&A …
Fidelity National Information Services Inc. (FIS) saw its stock rise by 5.27% to $44.13 on Thursday, outperforming the broader market, which also experienced a favorable trading session. The S&P 500 Index increased by 0.65%, and the Dow Jones Industrial Average rose by 0.13%. Despite …
Belite Bio (BLTE) shares increased by 12.9% following the FDA's acceptance and Priority Review designation for its New Drug Application for tinlarebant, aimed at treating Stargardt Disease Type 1. The PDUFA target action date is set for February 12, 2027, and if approved, tinlarebant …
Belite Bio (NASDAQ:BLTE) stock declined 7.2% to $166.11 on Thursday, with trading volume below its average. Despite the drop, analysts have a "Moderate Buy" consensus rating with an average price target of $204.40. The company, a clinical-stage biotechnology firm, reported a narrower-than-expected quarterly loss …
Fidelity National Information Services (FIS) stock has declined 36% year-to-date, primarily due to a broader fintech sector pullback and a significant guidance cut on August 4 related to its Capital Markets segment. Despite this, analysts maintain a bullish outlook with a mean target price …
(RTTNews) - Belite Bio, Inc (BLTE), a clinical-stage drug development company, announced its financial results for the second quarter, reflecting a wider net loss. The company also provided an update on its New Drug Application (NDA) for tinlarebant for the treatment of Stargardt disease …
Belite Bio announced that the FDA accepted its New Drug Application for tinlarebant with Priority Review for treating Stargardt disease type 1, setting a PDUFA target action date of February 12, 2027. Despite this regulatory progress, the company reported a wider net loss of …
Fidelity National Information Services (FIS) recently reported strong Q2 and H1 results, reaffirmed full-year revenue guidance, and maintained its quarterly dividend. The company also completed the global rollout of its Digital One Commercial platform into APAC, which is already being utilized by a major …
Belite Bio, Inc U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) with Priority Review for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); Prescription Drug User Fee Act (PDUFA) target action date of February 12, 2027 Company presented …
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 11 a.m. ET CALL PARTICIPANTS Senior Vice President, Investor and External Relations - Lisa Foxworthy-Parker Chief Executive Officer - Mike Nolan Executive Vice President and Chief Financial Officer - Anthony Park F&G Annuities …
Fidelity National Information Services Inc. (FIS) stock fell 1.96% to $41.92 on Wednesday, underperforming its competitors. This occurred on a mixed trading day where the S&P 500 rose 0.26% and the Dow Jones Industrial Average fell 0.04%. The company's stock is currently 42.50% below …
H.C. Wainwright has increased its price target for Belite Bio (NASDAQ:BLTE) to $214 from $200, maintaining a Buy rating, after the FDA granted Priority Review to the New Drug Application for tinlarebant, a treatment for Stargardt disease type 1. The drug, which has shown …
Wedge Capital Management L L P NC increased its stake in Fidelity National Financial (FNF) by 23.2%, acquiring an additional 134,228 shares, bringing its total holdings to 711,994 shares valued at $33.6 million. Institutional investors now own 81.17% of FNF. The company also announced …
The FDA has accepted Belite Bio's marketing application for its lead asset, tinlarebant, granting it priority review. This therapy targets an eye disease, and the FDA has set a target action date of February 12, 2027.
Fidelity National Financial (FNF) reported strong Q2 results, outperforming analyst expectations due to robust commercial transaction activity and cost control, despite a subdued residential market. CEO Mike Nolan highlighted momentum in daily opened orders and the positive impact of recruiting and tuck-in acquisitions. The …
Assenagon Asset Management S.A. has acquired 149,432 shares of Fidelity National Financial, Inc. (FNF) valued at approximately $7.05 million during the second quarter. This move comes as FNF reported strong quarterly earnings, beating analyst estimates with $1.39 EPS and an 11.4% revenue increase year-over-year. …
Belite Bio announced that the FDA has accepted and granted Priority Review for its New Drug Application (NDA) for tinlarebant, aimed at treating Stargardt Disease Type 1 (STGD1). The FDA set a PDUFA date of February 12, 2027, for a decision. The NDA is …
Search by ticker symbol or company name and select a result to open its chart.